Grace Therapeutics, Inc.(GRCE)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Grace Therapeutics, Inc. (GRCE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. GRCE is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 36 institutional filers currently hold this stock. Top institutional holders of GRCE by reported 13-F value include Cerity Partners, Eversept Partners, BANK OF AMERICA, based on the most recent SEC filings. GRCE trades on the Nasdaq exchange and files with the SEC under CIK 1444192. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GRCE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Grace Therapeutics, Inc. directly from SEC EDGAR.

Net Income

$-1.2M

GRCE key financials by period

Grace Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202210-K$100.0M$-9.8M-15.6%
FY 202110-K$196.0K$-19.7M—

Institutions holding GRCE

Institutional investors reporting a position in Grace Therapeutics, Inc. on SEC Form 13F.
InstitutionSharesValueReported
Cerity Partners849,055$1.9M2026-06-30
Eversept Partners772,900$1.8M2026-06-30
BANK OF AMERICA494,698$1.1M2026-06-30
VANGUARD CAPITAL MANAGEMENT411,714$934.6K2026-06-30
CITADEL ADVISORS349,740$793.9K2026-06-30
Maven Securities LTD200,000$454.0K2026-06-30
GROUP ONE TRADING, L.P.122,700$278.5K2026-06-30
Birchview Capital120,000$272.4K2026-06-30
CANTOR FITZGERALD, L. P.100,000$227.0K2026-06-30
TWO SIGMA INVESTMENTS96,890$219.9K2026-06-30
SEC EDGAR: CIK 1444192 →
GRCE

Grace Therapeutics, Inc.

GRCE
NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 36 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Net Income

Q1 2026
EDGAR

$-1.18M

EPS (Diluted)

Q1 2026
EDGAR

$-0.06

ROIC

Q1 2026
EDGAR

-18.8%

Top Institutional Holders

as of Q2 2026
$9.47M total
Cerity Partners LLC
$1.93M0.0%
Eversept Partners, LP
$1.75M+2.2%
BANK OF AMERICA CORP /DE/
$1.12M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$934.6K+2.5%
CITADEL ADVISORS LLC
$793.9K+254.2%
Maven Securities LTD
$454.0KNew
GROUP ONE TRADING, L.P.
$278.5K+2354.0%
Birchview Capital, LP
$272.4K+140.0%
CANTOR FITZGERALD, L. P.
$227.0KNew
TWO SIGMA INVESTMENTS, LP
$219.9KNew

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…